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Complications of Atrial Fibrillation Ablation. Introduction: Up to 6% of patients experience
complications after radiofrequency catheter ablation (RFA) of atrial fibrillation (AF). The purpose of this
study is to determine the prevalence and predictors of periprocedural complications after RFA for AF.
Methods and Results: The subjects were 1,295 consecutive patients (age = 60 ± 10 years) who underwent
RFA (n = 1,642) for paroxysmal (53%) or persistent AF (47%) from January 2007 to January 2010. A
complication occurred in 57 patients (3.5%); a vascular access complication in 31 (1.9%); pericardial
tamponade in 20 (1.2%); a thromboembolic event in 4 (0.2%); deep venous thrombosis in 1 (<0.01%); and
pulmonary vein stenosis in 1 patient (<0.01%). There were no procedure-related deaths. On multivariate
analysis, female gender (OR = 2.27; ±95% CI: 1.31–2.57, P < 0.01) and procedures performed in July or
August (OR = 2.10; ±95% CI: 1.16–3.80, P = 0.01) were independent predictors of any complication. For
vascular complications, treatment with clopidogrel (OR = 4.40; ±95% CI: 1.43–13.53, P = 0.01), female
gender (OR = 3.65; ±95% CI: 1.72–7.75, P < 0.01) and performing RFA in July or August (OR = 2.71;
±95% CI: 1.25–5.87, P = 0.01) were independent predictors. The only predictor of cardiac tamponade was
prior RFA (OR = 3.32; ±95% CI: 0.95–11.61; P < 0.05).
Conclusion: Prevalence of perioperative complications for RFA of AF is 3.5% and vascular access
complications constitute the majority. The need for clopidogrel therapy should be carefully considered
prior to RFA. At teaching institutions close supervision should be exercised during vascular access early
in the year. Improvements in ablation technology and elimination of the need for repeat procedures may
decrease the risk of pericardial tamponade. (J Cardiovasc Electrophysiol, Vol. 22, pp. 626-631, June 2011)
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Introduction
Radiofrequency catheter ablation (RFA) has proven to be
an effective treatment modality to eliminate atrial fibrillation
(AF). It is likely that worldwide adoption of RFA for AF will
continue to increase. Although effective, RFA also carries a
small but finite risk of serious complications. Major compli-
cations after RFA of AF have been reported in 1.4% to 6%
of patients in prior studies.1-3
The purpose of this study is to determine the risk factors
associated with perioperative complications in a large cohort
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of patients with AF who underwent RFA using the same
ablation technology at an academic teaching institution.
Methods
Study Subjects
The subjects of this study were 1,295 consecutive patients
who underwent 1,642 RFA procedures to eliminate paroxys-
mal (n = 870, 53%) or persistent AF (n = 772, 47%) between
January 2007 and January 2010. Consecutive patients were
enrolled from a 3-year interval during which ablation tech-
nique and the devices used for ablation were similar among
operators. The mean age of the patients was 60 ± 10 years
(range: 23–84 years). Of the procedures performed, 1,217
(74%) were in men and 425 (26%) were in women. The
mean left atrial size and left ventricular ejection fraction
were 41 ± 12 mm and 0.54 ± 0.22, respectively. The clinical
characteristics of the patients (per procedure) are shown in
Table 1.
Electrophysiologic Study and RFA
All patients provided informed written consent. An elec-
trophysiologic study was performed in the fasting state. All
antiarrhythmic drugs except amiodarone were discontinued
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TABLE 1
Characteristics of Procedures
Total Procedures No Complications Complications
(n = 1,642) (n = 1,585) (n = 57) P
Female gender 425 (26) 400 (25) 25 (44) <0.01
Age (years) 60 ± 10 60 ± 10 62 ± 10 0.14
Height (in) 70 ± 5 70 ± 4 69 ± 4 0.10
Weight (lbs) 215 ± 65 214 ± 48 208 ± 40 0.32
Persistent AF 772 (47) 751 (48) 21 (37) 0.14
Previous AF ablation 634 (39) 616 (42) 18 (35) 0.40
Hypertension 854 (53) 819 (52) 35 (61) 0.22
Coronary artery disease 259 (16) 248 (16) 11 (19) 0.49
CABG surgery 182 (11) 175 (11) 8 (14) 0.52
Hyperlipidemia 813 (50) 784 (50) 29 (51) 1.00
Diabetes mellitus 212 (13) 206 (13) 6 (10) 0.69
Hypertrophic cardiomyopathy 22 (1) 20 (1) 2 (4) 0.12
Gastroesophageal reflux disease 298 (18) 287 (18) 11 (19) 0.86
Hypothyroidism 278 (17) 271 (17) 7 (12) 0.37
Tobacco use 166 (10) 159 (10) 7 (12) 0.65
Clopidogrel 64 (4) 59 (4) 5 (9) 0.07
Aspirin 626 (39) 601 (39) 25 (45) 0.41
ACE inhibitors 371 (23) 361 (23) 10 (18) 0.42
Beta blockers 1,033 (65) 999 (65) 34 (61) 0.57
Amiodarone therapy 115 (7) 114 (7) 1 (2) 0.18
Antiarrhythmic drug therapy (other than amiodarone) 571 (36) 551 (36) 20 (36) 1.00
ARB 198 (12) 191 (12) 7 (13) 1.00
Calcium channel blockers 528 (33) 505 (33) 23 (41) 0.20
Digoxin 269 (17) 256 (17) 13 (23) 0.20
Statin 725 (45) 699 (45) 26 (46) 0.89
Ejection fraction 0.54 ± 0.22 0.56 ± 0.10 0.55 ± 0.11 0.65
Left atrial size (mm) 41 ± 12 44 ± 7 43 ± 7 0.20
Procedure in July or August 286 (17) 269 (17) 17 (30) 0.01
Total RF time 67 ± 29 68 ± 29 62 ± 24 0.24
Total fluoroscopy time 63 ± 24 63 ± 24 61 ± 21 0.64
Procedure time 280 ± 90 281 ± 80 279 ± 87 0.81
CTI line 249 (19) 244 (19) 5 (16) 0.82
Mitral/roof line 795 (48) 772 (49) 23 (40) 0.22
Ablation of complex electrograms 570 (35) 551 (35) 19 (33) 0.89
Values are n (%) or mean ± SD. AF = atrial fibrillation; CABG = coronary artery bypass graft surgery; ACE = angiotensin converting enzyme inhibitors;
ARB = angiotensin receptor blockers; CTI = cavotricuspid isthmus; RF = radiofrequency.
at least 4–5 half lives before the procedure. Amiodarone was
discontinued 8 weeks before the procedure. Three 8.0 to
8.5 Fr sheaths were inserted into the same femoral vein in
all cases. A multipolar electrode catheter was placed in the
coronary sinus for recording electrograms and for atrial pac-
ing. After transseptal access, systemic anticoagulation was
achieved with intravenous heparin to maintain an activated
clotting time of 300–350 seconds. A decapolar ring catheter
(Lasso, Biosense Webster, Diamond Bar, CA , USA) was
used to map pulmonary veins (PVs). An electroanatomical
mapping system (Carto, Biosense Webster) was used to re-
construct the 3-dimensional geometry of the left atrium and
PVs. Bipolar electrograms were displayed and recorded at
filter settings of 30 to 500 Hz (EPMed Systems).
All patients underwent antral PV isolation to isolate the
PVs using an open-irrigation, 3.5-mm-tip deflectable catheter
(Thermocool, Biosense Webster). Only an open-irrigation-
tip radiofrequency ablation catheter was used in all patients
in this study. Patients who underwent catheter ablation us-
ing any other device were excluded.4 Ablation of complex
fractionated atrial electrograms in the left and right atria,
coronary sinus, and linear ablation were performed at the
discretion of the operator. Radiofrequency energy was deliv-
ered at a maximum power output of 35 W at a flow rate of
30 mL/min and a maximum temperature of 48 ◦C. The power
was reduced to 20 to 25 W at a flow rate of 17 mL/min during
applications of energy near the PV ostia, posterior left atrium,
or in the coronary sinus. The esophagus was visualized by
barium swallow or an esophageal probe, and lesions close to
the esophagus were avoided as described previously.5 Anti-
coagulation was not reversed with protamine in any of the
patients after the procedure.
Postablation Management and Follow-Up
All patients were observed and had electrocardiographic
monitoring during an overnight hospital stay after the abla-
tion. Patients were discharged home taking warfarin and low
molecular weight heparin as a bridge to therapeutic anticoag-
ulation, if necessary. RFA was performed with a therapeutic
international normalized ratio (INR) (>2.0) in 198 patients
who therefore did not require low molecular weight heparin
(LMWH). Patients who were on an antiarrhythmic agent
prior to the procedure were maintained on the same regimen
for 8–12 weeks after the ablation procedure.
All patients were seen in an outpatient clinic 3 months
after the procedure and every 3–6 months thereafter. A re-
peat ablation procedure was offered to all patients with re-
current atrial arrhythmias. During repeat ablation, antral PV
isolation was confirmed and repeated as necessary. At the
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Figure 1. Types and frequency of complications after RFA for AF. DVT = deep venous thrombosis.
discretion of the operator, complex fractionated atrial elec-
trograms (CFAEs) were also targeted and eliminated and/or
linear ablation was performed.
Warfarin was discontinued in patients who were con-
firmed to be in sinus rhythm beyond 3 months after the final
ablation procedure as long as there was no history of throm-
boembolic events or another indication to continue anticoag-
ulant therapy.
Study Protocol
The study protocol was approved by the Institutional Re-
view Board. In this registry, data were acquired prospectively.
The primary endpoint of the study was major complications
that occurred ≤3 months after an index or repeat ablation pro-
cedure. Major complications were defined as: (1) a pericar-
dial effusion that required percutaneous or surgical drainage
or repair; (2) a peripheral vascular complication that required
blood transfusion or resulted in arteriovenous fistula, or pseu-
doaneurysm requiring percutaneous or surgical intervention
or longer hospital stay; (3) deep venous thrombosis (DVT);
(4) any thromboembolic event including transient ischemic
attack (TIA) or stroke; (5) pulmonary vein stenosis; (6) atri-
oesophageal fistula; (7) phrenic nerve palsy; and (8) death.
Statistical Analysis
Continuous variables were expressed as mean ± 1 stan-
dard deviation and were compared using a t-test. Normality
assumptions were first checked and found to be satisfied;
therefore, nonparametric tests were not used. Categorical
variables were expressed as counts and percentages and com-
pared using a Fisher’s exact test. Univariate parameters pos-
sibly associated (P < 0.15) with AF complications were then
included as candidate predictors in a stepwise multivariable
logistic regression analysis. All analyses were performed us-
ing SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Results of
the logistic regression model were presented as odds ratios
with 95% confidence intervals. In the case of the association
between cardiac tamponade and previous RFA, the Fisher’s
exact test and the Score test in the logistic regression model
both showed a significant association at a P < 0.05. A P <
0.05 indicated statistical significance.
Results
Prevalence of Complications
A complication occurred in 57 of 1,295 patients (4.4%)
and in 57 of 1,642 procedures (3.5%). In descending or-
der of prevalence, the complications were: a peripheral
vascular complication requiring transfusion, intervention,
or prolonged hospital stay in 31 patients (2.4% per pa-
tient and 1.9% per procedure); a pericardial effusion re-
quiring intervention in 20 patients (1.5% per patient and
1.2% per procedure); a thromboembolic event in 4 patients
(0.3% per patient and 0.2% per procedure) including a TIA
in 2 patients, a stroke with residual symptoms in 1 pa-
tient, and mesenteric embolism in 1 patient; PV stenosis
of 90% involving the left superior pulmonary vein in 1 pa-
tient (<0.01%); and DVT of the lower extremity in 1 pa-
tient (<0.01%). There was no phrenic nerve palsy, atrioe-
sophageal fistula, or procedure-related mortality (Figure 1).
Among the 1,295 patients, none experienced more than one
complication.
Procedural Characteristics, Repeat Ablation, and
Complications
The mean duration of RFA was 280 ± 90 minutes and
the mean duration of radiofrequency energy application was
67 ± 29 minutes. Six hundred and thirty-four of 1,642 pro-
cedures were a repeat ablation (39%).
There was no association between the ablation strategy
(P = 0.2), duration of radiofrequency energy application
(P = 0.2), and total procedure time (P = 0.8) and the proba-
bility of developing complications. However, a previous RFA
for AF was associated with a higher likelihood of pericardial
tamponade (OR = 3.32; ±95% CI: 0.95–11.61, P < 0.05
Fisher’s exact test).
Case Volume, Month of the Year, and Complications
There was no association between annual procedure vol-
ume and complications (P = 0.2). However, the probability
of overall complications was higher in the months of July or
August than the other months of the year (OR = 2.10; ±95%
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TABLE 2
Univariate Predictors of Complications
OR ±95% CI P
Age (years) 1.02 0.99–1.05 0.14
Female gender 2.32 1.36–3.95 <0.01
Persistent atrial fibrillation 1.54 0.89–2.67 0.12
Procedure performed 2.08 1.16–3.72 0.01
in July or August
Clopidogrel 2.50 0.99–6.47 0.06
CI: 1.16–3.80, P = 0.01). There was no relationship between
the time of the year, case volume, and risk of pericardial
tamponade (P = 0.2).
Predictors of Complications
On univariate analysis, among the clinical variables listed
in Table 1, female gender (OR = 2.32; ±95% CI: 1.36–
3.95, P < 0.01) and procedures performed in July or August
(OR = 2.08; ±95% CI: 1.16–3.72, P = 0.01) were associ-
ated with a higher probability of developing a complication
(Table 2).
Variables predictive of a complication with a P < 0.15
on univariate analysis were age (P = 0.14), female gen-
der (P < 0.01), persistent AF (P < 0.12), procedures per-
formed in July or August (P < 0.01), and clopidogrel therapy
(P = 0.06). Multivariate analysis incorporating these vari-
ables demonstrated that female gender (OR = 2.27; ±95%
CI: 1.31–2.57, P < 0.01) and procedures performed in July
or August (OR = 2.10; ±95% CI: 1.16–3.80, P = 0.01)
were independently associated with periprocedural compli-
cations. There was no significant interaction between these
variables.
Vascular Complications and Pericardial Tamponade
Vascular access complications constituted the majority of
complications in this study (54%). On multivariate analy-
sis, female gender (OR = 4.40; ±95% CI: 1.72–7.75, P <
0.01), clopidogrel therapy (OR = 4.70; ±95% CI: 1.43–
13.53, P = 0.01), and procedures performed in July or August
(OR = 2.71; ±95% CI: 1.25–5.87; P = 0.01) were indepen-
dent risk factors of a vascular complication. Among the 31
patients with a vascular complication, 12 patients had a major
hematoma that required transfusion, 17 patients had an arte-
riovenous fistula, and 2 patients had a pseudoaneurysm of the
femoral artery. Surgical repair was performed in 9 of 19 pa-
tients who had an arteriovenous fistula or pseudoaneurysm.
In the remaining patients, there was spontaneous resolution.
There was no difference in the prevalence of vascular and
other complications among patients who had RFA without
discontinuing warfarin and those who discontinued warfarin
and used LMWH as a bridge.
The second most prevalent complication was pericardial
tamponade, which accounted for 35% of all complications.
On multivariate analysis, prior RFA for AF was the only in-
dependent risk factor for pericardial tamponade (OR = 3.32;
±95% CI: 0.95–11.61, P < 0.05, Fisher’s exact test). In-




The main findings of this study demonstrate that: (1) at an
academic teaching institution, the complication rate of RFA
for AF is 3.5% per procedure, including a vascular compli-
cation in 1.9% and pericardial tamponade in 1.2% of the
patients; (2) female gender, procedures performed in July or
August, and therapy with clopidogrel are independent pre-
dictors of vascular complications, whereas a prior RFA for
AF is the only independent predictor of pericardial tampon-
ade; (3) the prevalence of thromboembolic events after RFA
of AF appear to be low, 0.2%; (4) there does not appear to be
any association between the ablation strategy, total duration
of radiofrequency energy application, total procedure time,
or case volume and the probability of developing a complica-
tion; and (5) with the ablation technique employed, the risk
of PV stenosis is very low, <0.1%, and there are no cases
of phrenic nerve palsy, atrioesophageal fistula, or procedure-
related deaths in >1,200 patients after >1,600 procedures.
Vascular Complications
In this study, female gender, clopidogrel therapy, and pro-
cedures performed in the months of July or August were in-
dependently associated with vascular complications. The ex-
planation for a gender difference in the prevalence of vascular
complications may be the variability in vascular anatomy be-
tween men and women. The ideal site for femoral venous
access should be through the common femoral vein since the
vessel is larger and easily compressible. However, women
have a significantly shorter common femoral artery than men
(37.9 ± 12.7 mm vs 46 ± 17.2 mm; P < 0.01),6 which may
lead to inadvertent access proximal or distal to the common
femoral vein.
The increased risk of procedure-related bleeding with
clopidogrel has been well established in the surgical liter-
ature and its use is a risk factor for peripheral vascular com-
plications in patients undergoing cardiac catheterization.7,8
Consistent with the findings of prior studies, the risk of vas-
cular complications was not any higher among the relatively
small group of patients who had a therapeutic INR during
the procedure than the rest of the study subjects who discon-
tinued warfarin and used LMWH prior to the procedure.9
This study demonstrated that procedure performed in July
or August is also an independent risk factor. The academic
year starts in the month of July and vascular access is usu-
ally the first task new trainees encounter. There are usually
8 trainees over a 2-year period. It has been long recognized
that complications may be higher early in the academic year
at teaching institutions, often referred to as the “July Ef-
fect.”10-12 However, in this study, except for vascular com-
plications there was no relationship between other compli-
cations and month of the year probably because of close
supervision of the trainees by experienced attending physi-
cians. Nevertheless, academic teaching institutions must be
aware of this “July Effect” and incorporate measures of close
supervision and review of the appropriate techniques to de-
crease the rate of complications, particularly vascular access.
One approach may involve limiting vascular access for RFA
procedures until sufficient proficiency is confirmed.
It is possible that placement of fewer venous sheaths
through the same femoral vein, particularly in women who
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have shorter veins, may reduce the risk of vascular compli-
cations. If mapping and ablation could be performed using
the same catheter, then one less venous sheath would be
necessary. Therefore, improvements in current ablation tech-
niques and technologies may also be helpful to decrease vas-
cular complications. Whether using a micropuncture venous
access technique with or without the guidance of vascular
ultrasound will reduce vascular complications remains to be
determined.
Pericardial Effusion and Cardiac Tamponade
Prior RFA for AF was an independent risk factor for peri-
cardial tamponade in this study. In a prior study, significant
variations in the transmural thickness of the left atrial my-
ocardium were reported.13 It is possible that variability in the
anatomy and tissue architecture of the left atrium may pre-
dispose to recurrent myocardial perforation and pericardial
tamponade.
Another study demonstrated that RFA results in scarring
and fibrosis of the atrial wall with subsequent thinning.14
With the use of open-irrigation catheters capable of creating
large transmural lesions, and with more extensive ablation
particularly in patients with persistent AF, prior RFA ap-
pears to be an important risk factor for pericardial tampon-
ade. This observation emphasizes the need to minimize the
extent of ablation by more precise and specific identification
and elimination of drivers of AF; to eliminate the need for
repeat ablation procedures as much as possible; and to im-
prove the existing ablation technologies such that extensive
fibrosis/scarring and myocardial thinning is minimized or
avoided at best. Whether high resolution imaging of the left
atrium and the PVs by MRI prior to RFA will be helpful to
identify anatomical variations and extent of myocardial scar-
ring and thinning particularly after previous RFA remains to
be determined.15
Thromboembolic Events
Thromboembolic events were observed in <0.5% of the
patients in this study. Experience of the operators with the
technique, immediate and aggressive intraprocedural antico-
agulation with a target activated clotting time (ACT) >300
seconds, bridging with LMWH and continuing anticoagula-
tion for ≥3 months after the RFA may have contributed to
the low incidence of thromboembolic events. Furthermore,
anticoagulation was never reversed with protamine, which
may predispose to a prothrombotic state early after the pro-
cedure. Performing RFA with a therapeutic INR may have
also prevented thromboembolic events at least among pa-
tients in whom warfarin was not discontinued prior to the
procedure.9
Case Volume, Atrioesophageal Fistula, Phrenic Nerve
Palsy, PV Stenosis, and Mortality
Atrioesophageal fistula has been reported as an infrequent,
however, potentially fatal complication of catheter ablation
along the posterior left atrium, particularly with ablation
catheters capable of creating large and deep lesions. After
recognition of this complication, the esophagus has been
routinely visualized by barium swallow and applications of
radiofrequency energy in the immediate proximity of the
esophagus have been minimized. Furthermore, the power
has been limited to a maximum of 25 W along the posterior
wall, and omeprazole has been prescribed for 2–4 weeks after
RFA to reduce gastric acidity. It is likely that these measures
have been helpful in prevention of atrioesophageal fistula in
>1,600 cases.
There were no cases of phrenic nerve palsy in this series
and PV stenosis of 90% occurred in only one PV, under-
scoring the importance of avoiding applications of radiofre-
quency energy within the PVs. However, because the PVs
were not routinely assessed after the RFA by CT or MRI,
it is possible that asymptomatic PV stenosis was not recog-
nized.
The annual case volume of the 9 operators in this study
was not associated with the risk of complications in this
study. However, each one of the operators in this study had
>5 years experience with RFA of AF and had performed at
least several hundred cases. There was no procedure-related
mortality in this study, reassuring the safety of the procedure.
Prior Studies
Previous studies have shown that complications of RFA
for AF are relatively common and should be carefully consid-
ered during patient selection. In a recent worldwide survey
that included 182 centers,16 the overall complication rate
was 4.5% with a similar frequency of tamponade and periph-
eral vascular complications, 1.3% and 1.5%, respectively.
In another multicenter registry from 32 centers, the overall
complication rate was 3.9%.2
Consistent with the findings of this study, a prior study
demonstrated that women were more likely to experience
vascular complications than men.7,17 An overall complica-
tion rate of 5% with age >70 years and female gender as
predictors of major complications were reported in another
study.18 However, the novel findings of this study include the
adverse effect of concomitant therapy with clopidogrel on
vascular complications, the higher risk of vascular complica-
tions early during the academic teaching year, and increased
risk of pericardial tamponade after prior RFA for AF.
Limitations
A limitation is that the findings of this study may not be ap-
plicable to other ablation strategies or technologies and only
relate to the technique described using an open-irrigation-tip
ablation catheter. A second limitation of this study is that,
because the event rate was small despite a large sample size,
all predictors of complications, particularly for the infrequent
ones, may not have been identified. Finally, this study was
performed at a single center and may not be generalized to
all practices.
Clinical Implications
Most of the perioperative complications of RFA for AF re-
late to vascular access, specifically in women and those who
receive clopidogrel. Therefore, caution should be exercised
and close supervision should be provided during obtaining
vascular access particularly early in the academic year. The
need to continue clopidogrel into the perioperative phase
should be carefully reviewed prior to the procedure. Abla-
tion strategies and technologies that eliminate the need for
insertion of multiple venous catheters may also be helpful in
reducing the risk of vascular complications.
Because prior RFA for AF is associated with an increased
risk of pericardial tamponade, limiting the extent of ablation,
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alternative sources of energy or ablation technologies that
do not result in extensive myocardial scarring and thinning,
improvements in ablation techniques that reduce the need for
repeat procedures, and imaging of the atrial myocardium and
atrial geometry prior to ablation may be helpful to reduce the
risk of tamponade.
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